About Us
Contact Us

Emerging Pharma Discovery (EPD) Consulting

Building Strategies to Transform Research from Discovery to Clinic

Dr. Marisela Rodriguez, PhD

Drug Development Strategist

Founder, Advisor & Executive Consultant

Purpose

We help drug and platform developers make the right choices to strengthen roadmap planning, improve clinicalreadiness, and support investor engagement.

Applying Proven Strategic Frameworks into Early Drug Development

Enabling smarter decision-making

Lowering R&D costs

Streamlining the path to clinic

Proven Expertise to Accelerate Your Path from Discovery Through Phase I


Managed €150M+ portfolio at BioNTech in Mainz, Germany


Guided 7 Program Managers to advance 11 global preclinical and clinical programs at various development stages


Led 100+ subject-matter experts across various multidisciplinary drug development programs


Blending experience from industry, government and academia



Worked in Collaboration with:


WHO

World Health Organization

CDC

Center for Disease Control and Prevention

NIH

National Institutes of Health

USDA

US Department of Agriculture

GF

Gates Foundation

GAVI

The Vaccine Alliance



Decades of Expertise. Proven Results. Strategic Impact.


25+

Years in infectious disease preclinical research

15+

License acquisitions for critical assets

7.5

Years in project & portfolio management


Drug Development Errors can Lead to Substantial Financial Losses


The reality for researchers is more daunting.


90% of Drug Programs Fail Before Reaching Phase I due to:


Lack of preclinical efficacy

Unclear Target Product Profile (TPP)
Manufacturing challenges
Unmanageable toxicity

Providing strategic guidance and expert insights to increase the likelihood of clinical success

Citations

1 Sertkaya A, Beleche T, Jessup A, Sommers BD. JAMA Netw Open. 2024;7(6):e2415445. ​doi:10.1001/jamanetworkopen.2024.15445

2 Wouters OJ, McKee M, Luyten J., 2009-2018. JAMA. 2020;323(9):844–853. doi:10.1001/jama.2020.1166

3 DiMasi JA, Hansen RW, Grabowski., 2009-2018. J. Health Econ. 2016;47:20–33. doi:10.1016/j.jhealeco.2016.01.012

4 Hingorani et al. Sci. Rep. (2019) 9:18911. doi.org/10.1038/s41598-019-54849-w

5 Strovel J, Sittampalam S, Coussens NP, et al. Assay Guidance Manual, 2012 May 1 (Updated 2016 Jul 1).

EPD consulting helps drug innovators avoid early development missteps that can drive R&D costs up by:


40%


Dodging pitfalls can save millions in drug development costs.

Citations

4 Hingorani et al. Sci. Rep. (2019) 9:18911. doi.org/10.1038/s41598-019-54849-w

5 Strovel J, Sittampalam S, Coussens NP, et al. Assay Guidance Manual, 2012 May 1 (Updated 2016 Jul 1).

Partnering with Stakeholders Across Emerging Biopharma


Biotech Start-Ups


Venture Capital Firms


Academic Research Labs


Nonprofit Organizations & Coalitions

Biohubs & Accelerators



Bring clarity to your drug development journey


Ready to accelerate your program(s)?